Ivacaftor, a CFTR potentiator for CF patients carrying gating mutations such as G551D, has demonstrated impressive pulmonary outcomes, including reduction in pulmonary exacerbations, and improved lung function20–22. Here, CFTR is linked to cystic fibrosis.